N-Acetyl Selank - 20MG

Selank

Selank is a synthetic heptapeptide nootropic and anxiolytic that reduces anxiety, improves mood, and supports cognition without the sedation, memory impairment, or dependence risks typical of benzodiazepines.^[1–3]

Mechanism of Action

• GABA_A positive allosteric modulator: Subtype-selective, concentration-dependent modulation of GABAergic neurotransmission; distinct from but partially overlapping benzodiazepines. Supported by radioligand binding and cortical gene-expression studies.^[1–3]
• Network effects: Context-dependent interaction with other GABAergic agents (e.g., diazepam, olanzapine); possible ancillary influence on serotonergic pathways implicated in mood and anxiety.^[1,3–6]

Efficacy & Cognition

• Anxiolytic efficacy comparable to classical benzodiazepines without sedation or cognitive impairment; anti-amnesic properties reported.^[1–3][8]
• Improvements in memory, focus, and learning via modulation of neurotransmitter and neuropeptide signaling.^[1–3][7]

Immunomodulatory Profile

• Modulates inflammation/immune-response genes (e.g., downregulates complement C3; affects cytokine-related genes), suggesting support of immune homeostasis and reduced inflammation.^[9]

Dosing & Safety (Research)

• Typical ranges: 0.15–0.3 mg per administration intranasally or subcutaneously; 10 mg reflects a higher research dose—long-term safety at this dose not fully established in literature.^[1–3]
• Generally well tolerated in preclinical/clinical settings; no dependence, withdrawal, or benzodiazepine-like cognitive adverse effects observed.^[1–3]

References

1. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Protein Pept Lett. 2018;25(10):914-923.
2. Volkova A, Shadrina M, Kolomin T, et al. Front Pharmacol. 2016;7:31.
3. Filatova E, Kasian A, Kolomin T, et al. Front Pharmacol. 2017;8:89.
4. Santarelli L, Gobbi G, Debs PC, et al. PNAS. 2001;98(4):1912-1917.
5. Lin EJ. Curr Pharm Des. 2012;18(35):5709-5727.
6. Kormos V, Gaszner B. Neuropeptides. 2013;47(6):401-419.
7. Khan H, Khattak S, Mubarak MS, et al. CNS Neurol Disord Drug Targets. 2018;17(1):9-13.
8. Wilhelm EA, Torres MLCP, Pereira CF, et al. Can J Physiol Pharmacol. 2020;98(5):304-313.
9. Kolomin T, Morozova M, Volkova A, et al. Mol Immunol. 2014;58(1):50-55.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles by preparing small aliquots.
• Solvent compatibility: Use a sterile, compatible solvent per your protocol; filter-sterilize if required.
• Labeling: Clearly label aliquots with concentration, solvent, and preparation date.

Storage guidance is general for research peptides and may be adapted to your lab SOP.